Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (36)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Baxter, S.W.
Right arrow Articles by Campbell, I.G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Baxter, S.W.
Right arrow Articles by Campbell, I.G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Carcinogenesis, Vol. 22, No. 2, 347-349, February 2001
© 2001 Oxford University Press

SHORT COMMUNICATION

Polymorphic variation in CYP19 and the risk of breast cancer

S.W. Baxter, D.Y.H. Choong, D.M. Eccles and I.G. Campbell2

VBCRC Cancer Genetics Laboratory, Peter MacCallum Cancer Institute, Locked Bag No. 1 A'Beckett St., Victoria 8006, Australia and
1 Wessex Clinical Genetics Service, Princess Anne Hospital, Coxford Road, Southampton SO16 5YA, UK

The production of estrogen from androgen via the estrogen biosynthesis pathway is catalyzed by aromatase P450 (cyp19). We have assessed the frequency of allelic variants of the CYP19 intron 4 [TTTA]n repeat in 327 breast cancer cases and 253 controls from southern England. Previous studies have suggested that the [TTTA]10 repeat and [TTTA]12 repeat variants represent low penetrance breast cancer susceptibility alleles. Compared with controls our breast cancer cases had a statistically significant positive association with the [TTTA]10 allele (1.5 versus 0.2%, P = 0.028) and the [TTTA]8 allele (13.5 versus 8.7%, P = 0.012). The frequency of the [TTTA]12 allele was not significantly elevated in our study group compared with controls (2.3 versus 2.2%, P = 1.00). The CYP19 intron 4 [TTTA]n repeat is unlikely to have a functional effect on aromatase activity and it is more likely that the [TTTA]8 and [TTTA]10 variants are in linkage disequilibrium with other functional CYP19 variants.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
Q. Cai, N. Kataoka, C. Li, W. Wen, J. R. Smith, Y.-T. Gao, X. O. Shu, and W. Zheng
Haplotype Analyses of CYP19A1 Gene Variants and Breast Cancer Risk: Results from the Shanghai Breast Cancer Study
Cancer Epidemiol. Biomarkers Prev., January 1, 2008; 17(1): 27 - 32.
[Abstract] [Full Text] [PDF]

Home page
 Am J EpidemiolHome page
S. H. Olson, E. V. Bandera, and I. Orlow
Variants in Estrogen Biosynthesis Genes, Sex Steroid Hormone Levels, and Endometrial Cancer: A HuGE Review
Am. J. Epidemiol., February 1, 2007; 165(3): 235 - 245.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
J.-R. Long, N. Kataoka, X.-O. Shu, W. Wen, Y.-T. Gao, Q. Cai, and W. Zheng
Genetic Polymorphisms of the CYP19A1 Gene and Breast Cancer Survival.
Cancer Epidemiol. Biomarkers Prev., November 1, 2006; 15(11): 2115 - 2122.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
Y. Guo, D.-H. Xiong, T.-L. Yang, Y.-F. Guo, R. R. Recker, and H.-W. Deng
Polymorphisms of estrogen-biosynthesis genes CYP17 and CYP19 may influence age at menarche: a genetic association study in Caucasian females
Hum. Mol. Genet., August 15, 2006; 15(16): 2401 - 2408.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. X. Ma, A. A. Adjei, O. E. Salavaggione, J. Coronel, L. Pelleymounter, L. Wang, B. W. Eckloff, D. Schaid, E. D. Wieben, A. A. Adjei, et al.
Human Aromatase: Gene Resequencing and Functional Genomics
Cancer Res., December 1, 2005; 65(23): 11071 - 11082.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
I. M. Dick, A. Devine, and R. L. Prince
Association of an aromatase TTTA repeat polymorphism with circulating estrogen, bone structure, and biochemistry in older women
Am J Physiol Endocrinol Metab, May 1, 2005; 288(5): E989 - E995.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
B. K. Dunn, D. L. Wickerham, and L. G. Ford
Prevention of Hormone-Related Cancers: Breast Cancer
J. Clin. Oncol., January 10, 2005; 23(2): 357 - 367.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
K. Hirose, K. Matsuo, T. Toyama, H. Iwata, N. Hamajima, and K. Tajima
The CYP19 Gene Codon 39 Trp/Arg Polymorphism Increases Breast Cancer Risk in Subsets of Premenopausal Japanese
Cancer Epidemiol. Biomarkers Prev., August 1, 2004; 13(8): 1407 - 1411.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
J. Somner, S. McLellan, J. Cheung, Y. T. Mak, M. L. Frost, K. M. Knapp, A. S. Wierzbicki, M. Wheeler, I. Fogelman, S. H. Ralston, et al.
Polymorphisms in the P450 c17 (17-Hydroxylase/17,20-Lyase) and P450 c19 (Aromatase) Genes: Association with Serum Sex Steroid Concentrations and Bone Mineral Density in Postmenopausal Women
J. Clin. Endocrinol. Metab., January 1, 2004; 89(1): 344 - 351.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Angele, P. Romestaing, N. Moullan, M. Vuillaume, B. Chapot, M. Friesen, W. Jongmans, D. G. Cox, P. Pisani, J.-P. Gerard, et al.
ATMHaplotypes and Cellular Response to DNA Damage: Association with Breast Cancer Risk and Clinical Radiosensitivity
Cancer Res., December 15, 2003; 63(24): 8717 - 8725.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.